News & Updates

Show Multimedia Only

[Infographics] ARNI: First-line RASI in 4-pillar GDMT for HFrEF

15 Jan 2025

2024 American College of Cardiology’s Expert Consensus Decision Pathway for Treatment of Heart Failure with Reduced Ejection Fraction (HFrEF), the most recent international guidance on HFrEF treatment, recommends angiotensin receptor/neprilysin inhibitor (ARNI; ie, sacubitril/valsartan) as the preferred renin-angiotensin system inhibitor (RASI), which should be used as first-line therapy whenever possible. Emphasis is placed on initiating and titrating guideline-directed medical therapy (GDMT) early and rapidly. Here is why and how.

[Infographics] ARNI: First-line RASI in 4-pillar GDMT for HFrEF

15 Jan 2025

Potassium binder allows optimized MRA therapy in hyperkalaemic HFrEF patients

15 Jan 2025 by

Treatment with the potassium binder sodium zirconium cyclosilicate (SZC) stabilizes potassium levels in patients with heart failure with reduced ejection fraction (HFrEF) during spironolactone optimization, as shown in the prospective, randomized-withdrawal REALIZE-K trial.

Potassium binder allows optimized MRA therapy in hyperkalaemic HFrEF patients

15 Jan 2025

Coffee drinking for longevity? Timing may be key

13 Jan 2025 by

Coffee’s beneficial effect on mortality may be time-dependent, with a study showing a strong association between lower mortality risk and coffee consumed in the morning.

Coffee drinking for longevity? Timing may be key

13 Jan 2025

Anti-CGRP monoclonal antibodies pose no increased CVD risk

11 Jan 2025

Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor do not appear to contribute to heightened risk of cardiovascular disease (CVD) relative to onabotulinumtoxinA in adults with migraine at high CVD risk, according to a study.

Anti-CGRP monoclonal antibodies pose no increased CVD risk

11 Jan 2025

Lipoprotein(a)-lowering with zerlasiran succeeds in phase II trial

08 Jan 2025

The small-interfering RNA zerlasiran appears promising in the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), reducing time time-averaged lipoprotein(a) concentration by more than 80 percent over 36 weeks of follow-up, as shown in a phase II trial.

Lipoprotein(a)-lowering with zerlasiran succeeds in phase II trial

08 Jan 2025

Mavacamten obviates long-term need for invasive septal reduction therapy in obstructive HCM

07 Jan 2025 by

Treatment with the allosteric cardiac myosin inhibitor mavacamten in severely symptomatic patients with obstructive HCM allows for the deferral of invasive SRT for nearly 2.5 years, as shown in the end-of-trial results of VALOR-HCM presented at AHA 2024

Mavacamten obviates long-term need for invasive septal reduction therapy in obstructive HCM

07 Jan 2025

Vitamin D may protect against young-onset ischaemic stroke

06 Jan 2025 by

Vitamin D may protect against young-onset ischaemic stroke through preventing atrial fibrillation (AF), a University of Hong Kong (HKU) study on Southern Chinese has found.

Vitamin D may protect against young-onset ischaemic stroke

06 Jan 2025

Physical prehabilitation beneficial for prefrail/frail patients’ recovery after cardiac surgery

06 Jan 2025 by

Vulnerable or frail patients who received physical prehabilitation, compared with those who received usual care, had clinically meaningful decrease in disability scores at 90 days after cardiac surgery, a Chinese University of Hong Kong (CUHK) study found.